623562-56-1

Basic information

• Product Name: 4-[3-(Boc-aMino)propyloxyl]aniline
• Synonyms: 4-[3-(Boc-aMino)propyloxyl]aniline;tert-Butyl (3-(4-aminophenoxy)propyl)carbamate;tert-butyl N-[3-(4-aminophenoxy)propyl]carbamate
• CAS NO: 623562-56-1
• Molecular Formula: C₁₄H₂₂N₂O₃
• Molecular Weight: 266.33608
• Mol File: 623562-56-1.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-[3-(Boc-aMino)propyloxyl]aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[3-(Boc-aMino)propyloxyl]aniline(623562-56-1)
• EPA Substance Registry System: 4-[3-(Boc-aMino)propyloxyl]aniline(623562-56-1)

Safety Data

• Hazardous Substances Data: 623562-56-1(Hazardous Substances Data)

Upstream product

• 588-53-4 4-benzylidenamino-phenol 
• 83948-53-2 3-bromopropylamine tert-butylcarbamate 
• 100-02-7 4-nitro-phenol 
• 58885-58-8 N-tert-butoxycarbonyl-3-aminopropanol 
• 350-46-9 4-Fluoronitrobenzene 
• 123-30-8 4-amino-phenol 
• 116861-31-5 tert-butyl N-(3-chloropropyl)carbamate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 623562-63-0 [3-(4-nitro-phenoxy)-propyl]-carbamic acid tert-butyl ester 

Downstream Products

• 1448718-84-0 (S)-3-amino-N-[4-(3-tert-butoxycarbonylamino-propoxy)-phenyl]-succinamic acid tert-butyl ester 
• 1448718-87-3 (S)-N-[4-(3-amino-propoxy)-phenyl]-3-(2-(3-(guanidino)-benzoylamino)-acetylamino)-succinamic acid trifluoroacetate 
• 1448718-88-4 (S)-N-[4-[3-[[3-[2-[2-[2-[2-[2-[2-[2-[2-[3-(2,5-dioxo-2,5-dihydro-pyrrol-1-yl)-propionylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-1-oxopropyl]amino]propoxy]-phenyl]-3-[2-[3-[guanidino]-benzoylamino]-acetylamino]-succinamic acid 
• 1448718-83-9 (S)-N-[4-(3-tert-butoxycarbonylamino-propoxy)-phenyl]-3-(9H-fluoren-9-ylmethoxycarbonylamino )-succinamic acid tert-butyl ester 

Relevant articles and documents

BIOAVAILABLE PROTEIN DISULFIDE ISOMERASE INHIBITORS

Compounds according to formula (I) are described wherein R1 is an amino acid or a modified amino acid linked to the compound through a peptide bond, R2 is selected from CN, SO2CH3, NO2, CO2R3, CONHR3, NH2, NMe2 and CF3, and R3 is selected from H or lower alkyl, X is O or S, and Y is C-H or N, or a pharmaceutically acceptable salt thereof. The compounds can be used as protein disulfide isomerase inhibitors. The compounds can also be used in a method of treating or cancer in a subject.

HETEROAROMATIC MACROCYCLIC DERIVATIVES AS PROTEIN KINASE INHIBITORS

The present invention relates to a 2,7-substituted cyano[3,2-d]pyrimidine cyclic compound having protein kinase inhibitory activity, a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for preventing, alleviating, or treating a disease caused by abnormal cell growth, which includes the compound as an active ingredient. The novel 2,7-substituted cyano[3,2-d]pyrimidine cyclic compound of the present invention exhibits an excellent effect of inhibiting various protein kinases involved in the signal transduction of growth factors, and thus is effective as an agent for preventing, alleviating, or treating an abnormal cell growth disease caused by these protein kinases.

OXOINDOLINE DERIVATIVES AS PROTEIN FUNCTION MODULATORS

The present invention provides chimeric compounds of formula (II) that modulate protein function, to restore protein homeostasis, including cytokine, aiolos, and/or ikaros activity, TNF-alpha activity, CKl-alpha activity and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of protein-mediated diseases, disorders, and conditions, such as cytokine-mediated diseases, disorders, and conditions, including inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant rejection, and cancer, are provided.